Exhibit 4.2

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT

CHINA JO-JO DRUGSTORES, INC.

THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 1, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from CHINA JO-JO DRUGSTORES, INC., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, dated as of May 31, 2020, by an between the Company and H.C. Wainwright & Co., LLC.

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated June 1, 2020, among the Company and the purchasers signatory thereto.

Section 2. Exercise.

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $2.57, subject to adjustment hereunder (the “Exercise Price”).

c）无障碍运动如果在行使本条时没有有效的注册声明登记,或其中所载的招股说明书无法向持有人发行担保股份,则本担保也可在该时间全部或部分行使,方式是"无现金行使" ,其中持有人有权获得等于除以【 （A-B） （X） 】除以（A）所得商数的若干担保股份,而:

（A） =如该行使通知书是在紧接适用的行使通知书的日期前的交易日（1）在并非交易日的交易日依据本条第2（a）条执行及交付的,或（2）在根据联邦证券法）在这样的交易日,（ii）由持有人选择,（y）在紧接适用的行使通知书日期之前的交易日的VWAP,或（z）彭博信息通讯社（Bloomberg L.P. ）报告的主要交易市场普通股的投标价格,如该行使通知书是在交易日的"正常交易时间"内执行的,则该行使通知书须在交易日的两（2）小时内（包括在交易日后两（2）小时内（包括在交易日后两（2）小时内）交付根据本条例第2（a）条或（iii）条在适用的行使通知书的日期当日截止"正常交易时间" ,但该行使通知书的日期为交易日,而该行使通知书是在该交易日的"正常交易时间"结束后根据本条例第2（a）条执行和交付的；

（B） =经调整的本证行使价格；及

（X） =按照本担保条款行使本担保时可发行的担保股份数目,如果这种行使是通过现金行使而不是无现金行使。

"投标价格"就任何日期而言,指由以下第一项适用的条文所厘定的价格: （a）如该普通股在交易市场上市或报价,（b）该普通股在当时的交易市场（或最近的前一日期）的投标价格,而该交易市场当时的普通股是按Bloomberg L.P.的报告在该交易市场上市或报价的。 （根据交易日上午9时30分（纽约市时间）至下午4时20分（纽约市时间） ） , （b）如该普通股当时并非在交易市场上市或报价,（c）如果普通股没有在OTCQB或OTCQX上上市或报价,并且普通股的价格随后在粉红色公开市场（或继承其报价职能的类似组织或机构）上报告,则所报告的普通股每股最近的报价,（d）在所有其他情况下,由当时为证券的利益而由多数股东以诚意选定的独立评估人确定的普通股股份的公允市场价值,而该价值是公司合理接受的,其费用和开支应由公司支付。

“Vwap "就任何日期而言,指由以下第一项适用的条文所厘定的价格: （a）如该普通股在交易市场上市或报价,（b）上述日期（或最近的前一日期）的普通股每日成交量加权平均价格,而该日期的普通股随后在交易市场上上市或报价,正如彭博社（Bloomberg L.P. ）所报告的。 （根据交易日上午9时30分（纽约市时间）至下午4时22分（纽约市时间） ） , （b）如该普通股当时并非在交易市场上市或报价,（c）普通股在OTCQB或OTCQX上的上市或报价,而普通股的价格则在粉红色公开市场（或继承其报价职能的类似组织或机构）报告,（d）在所有其他情况下,由当时为证券的利益而由多数股东以诚意选定的独立评估人确定的普通股股份的公允市场价值,而该价值是公司可合理接受的,其费用和开支应由公司支付。

如果以这种无现金行使方式发行权证股份,当事人承认并同意,根据《证券法》第3（a） （9）节,权证股份应具有行使权证的特点,发行权证股份的持有期可附加于本权证的持有期。本公司同意不采取任何违反本条第2（c）款的立场。

d）运动技巧.

ii 行使新权证后交付如本权证已部分行使,则公司须应持有人的要求,并在交付本权证证明书时,向持有人交付一份新的权证,证明持有人有权购买本权证所要求的未买卖权证股份,而新的权证在所有其他方面均须与本权证相同。

三撤销权如果公司没有安排转让代理人按照第2（d） （i）条在转让证券交付日期之前向持有人转让证券股份,则持有人有权撤销这种行使。

四因未能及时交付认股权证而买入的补偿除了持有人可享有的任何其他权利外,如公司没有安排转让代理人按照上文第2（d） （i）条的规定,在证券交付日期当日或之前行使权证股份,而在该日期之后,持有人的经纪人要求其购买（在公开市场交易或其他方式中）或持有人的经纪公司以其他方式购买权证股份,证券持有人在行使该等权证股份时预期会收到该等权证股份的出售（a）买入" ） ,则公司须（A）以现金向持有人支付（如有的话）持有人的总购买价（包括经纪佣金,（如有的话）就如此购买的普通股而言,超过（y）乘以（1）本公司在发行时就行使该购买义务而须向持有人交付的担保股份数目（2）执行引起该购买义务的出售命令的价格,以及（B）持有人的选择,要么恢复未履行此种行使的权证部分和同等数量的权证股份（在这种情况下,这种行使应视为撤销） ,要么将如果公司及时履行其在本公司的行使和交付义务本应发行的普通股股份数量交付给持有人。例如,如果持有人购买总价为11,000美元的普通股,以支付购买-对于试图行使总价为10,000美元的普通股的购买,根据前一句（A）款,公司须向持有人支付1,000美元。持有人须向公司提供书面通知,指明就买入而须向持有人支付的款额,并应公司要求,提供有关该损失款额的证据。本协议不得限制持有人根据本协议、法律或股本可采取的任何其他补救措施的权利,包括但不限于对公司在行使本协议规定的权证时未能及时交付普通股的具体履行法令和/或强制性救济。例如,如果持有人购买总价为11,000美元的普通股,以支付购买-对于试图行使总价为10,000美元的普通股的购买,根据前一句（A）款,公司须向持有人支付1,000美元。持有人须向公司提供书面通知,指明就买入而须向持有人支付的款额,并应公司要求,提供有关该损失款额的证据。本协议不得限制持有人根据本协议、法律或股本可采取的任何其他补救措施的权利,包括但不限于对公司在行使本协议规定的权证时未能及时交付普通股的具体履行法令和/或强制性救济。

v 没有部分股份或股票本担保行使后,不得发行代表分数股份的分数股份或代表分数股份的股票。至于持有人在行使该等权力时有权购买的股份的任何部分,公司须在其选举中,就该部分的最后部分支付相当于该部分乘以行使价格的数额的现金调整,或将该部分合计至下一部分。

vi 收费、税收和开支发行该等权证股份的任何发行或转让税或其他附带费用,均须免费向持有人收取,而该等权证股份的发行或转让税或附带费用均须由公司支付,而该等权证股份须以持有人的名义或以持有人指示的一名或多于一名的名义发行；提供, 然而如证券股份以持有人名称以外的名义发行,则本证券在交还行使时,须附有由持有人妥为签立的转让表格,而公司可规定作为条件,支付足以偿还该证券附带的任何转让税的款项。本公司须向存托信托公司（或另一间执行类似职能的成立结算公司）支付当日处理任何行使通知书所需的所有转让代理费,以及向当日以电子方式交付担保股份所需的所有费用。

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61^st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

Section 3. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (提供, 然而, that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c）Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (提供, 然而, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d）Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction).  The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

f) 通知持有人.

i 行使价格调整凡按照本条第3条的任何条文调整行动价格,公司须迅速以传真或电邮方式,向持有人送交一份通知,说明调整后的行动价格,以及由此而导致的对担保股份数目的调整,并就需要作出调整的事实作出简短陈述。

ii 允许持有人行使的通知（A）公司须在普通股上宣布股息（或任何其他形式的分配） ； （B）公司须在普通股上宣布特别的非经常性现金股息或赎回； （C）公司须授权批给所有普通股权利或权证持有人,以认购或购买任何类别的资本股票或任何权利的股份,（D）公司的任何股东须就公司股票的任何重新分类、公司为其中一方的任何合并或合并、公司全部或实质上全部资产的出售或转让、或任何强制性股票交易所而将公司股票转换为其他证券、现金或财产,或（E）公司须授权自愿或非自愿解散,公司事务的清算或清盘,则在每宗个案中,公司须安排以传真或电邮方式,将其最后传真号码或电邮地址送交持有人,而该传真或电邮地址须在公司的证书登记册上显示,最少须在下文指明的适用纪录或生效日期前20个历日,（x）为该等股息、分发、赎回、权利或认股权证的目的而须作出纪录的日期,或如该纪录不须作出,则须决定该等股息、分发、赎回、权利或认股权证的持有人有权获得该等股息、权利或认股权证的日期,或（y）该等重新分类、合并、合并、出售的日期,预计转让或股票交易所将生效或结束,而预计普通股票记录持有人有权在重新分类、合并、合并、出售时,将其普通股票的股份交换为证券、现金或其他可交付财产,转让或股票交易；但没有交付该通知或该通知或该通知在交付时有任何缺陷,不影响该通知所规定的公司诉讼的有效性。凡本保证所提供的任何通知构成或载有关于本公司或任何附属公司的重要非公开资料,本公司须同时根据本报告表8-K向监察委员会提交该通知。持有人有权在该通知的日期起计至触发该通知的事件的生效日期的期间内行使本证,但本文另有明确规定的除外。凡本保证所提供的任何通知构成或载有关于本公司或任何附属公司的重要非公开资料,本公司须同时根据本报告表8-K向监察委员会提交该通知。持有人有权在该通知的日期起计至触发该通知的事件的生效日期的期间内行使本证,但本文另有明确规定的除外。

第4节. 手令的移交.

a) 可转让性根据FINRA第5110（g） （1）条,本担保书或在行使本担保书时发行的任何担保股份,不得出售、转让、转让、质押或抵押,也不得作为任何套期保值、短期出售、衍生产品的标的,将导致任何人有效经济处置证券的交易,其期限为紧接发出本证书所依据的要约的生效日期或开始销售日期后180天,但任何担保的转让除外:

在符合上述限制的前提下,并在符合任何适用的证券法律和本条例第4（d）条所列条件以及《采购协议》第4.1条的规定的前提下,本担保书和本担保书下的所有权利（包括但不限于任何登记权）在本担保书交出后,可全部或部分地转让给本公司或其指定代理人,连同本证的书面转让,大致采用持有人或其代理人或代理人正式签署的附件所附的形式,以及足以支付在转让时须缴付的任何转让税的资金。在交出后,如有需要,公司须以受让人或受让人（视乎情况而定）的名义,以及以该转让文书所指明的面额,签立和交付一份新的担保书或担保书,并须向转让人发出一份新的担保书,证明本担保书中未如此转让的部分,而本担保书即时取消。尽管本文另有相反的规定,除非持有人已将本证书全部转让给公司,否则持有人无须将本证书实际交还给公司,在此情况下,持有人须在持有人向公司交付转让表格全部转让本证书之日起三（3）个交易日内将本证书交还给公司。如果按照本合同适当分配,新持有人可以在没有发行新证书的情况下行使该证书购买证券股份。在交出后,如有需要,公司须以受让人或受让人（视乎情况而定）的名义,以及以该转让文书所指明的面额,签立和交付一份新的担保书或担保书,并须向转让人发出一份新的担保书,证明本担保书中未如此转让的部分,而本担保书即时取消。尽管本文另有相反的规定,除非持有人已将本证书全部转让给公司,否则持有人无须将本证书实际交还给公司,在此情况下,持有人须在持有人向公司交付转让表格全部转让本证书之日起三（3）个交易日内将本证书交还给公司。如果按照本合同适当分配,新持有人可以在没有发行新证书的情况下行使该证书购买证券股份。

b) 新授权书本担保书可与其他担保书分开或结合,一并在本公司上述办事处提交,并附有一份书面通知,指明新担保书的签发名称和面额,由持有人或其代理人或代理人签署。在符合第4（a）条的规定下,就任何可能涉及该等分部或组合的转让而言,公司须签立和交付一份或多于一份新的证书,以换取按照该通知将该等证书或证书分割或组合。所有在转让或交易时发行的担保书均应注明本担保书的发行日期,并应与本担保书相同,但依据本担保书发行的担保股份数目除外。

c）证书登记册本公司须在本公司为该目的而备存的纪录（以下简称"纪录" ）后,将本证书注册证书登记册" ） ,以记录持有者的名义在此不时。本公司可在没有实际相反通知的情况下,将本担保书的注册持有人视为本担保书的绝对拥有人,或将本担保书的任何行使或分配给本担保人。

d）转让限制如果在交出与本证书的任何转让有关的本证书时,本证书的转让不应（i）根据《证券法》和适用的国家证券或蓝天法律的有效登记声明进行登记,或（ii）在没有数量或销售方式限制或根据细则144规定的现行公共信息要求的情况下有资格转让,作为允许这种转让的条件,本证书的持有人或受让人（视属何情况而定）须遵守《采购协议》第5.7条的规定。

e) 持有人的代表持有人通过本合同的接受,表示并保证其正在获得本合同,并在任何行使本合同时,将获得本合同可发行的合同股份,以其本身的帐户为目的,而不是为了违反《证券法》或任何适用的国家证券法,分发或转售这种合同股份或其任何部分,除非依据《证券法》登记或豁免的销售。

第5节. 杂项.

a) 在没有股东权利之前锻炼；没有现金结算。本担保并不赋予持有人在行使第2（d） （i）条所列的表决权、股息或作为公司股东的其他权利,除非第3条另有明确规定。在不限制持有人在"无现金行使"时获得担保股份的权利,以及根据第2（d） （i）及2（d） （iv）条预期获得现金付款的权利的情况下,公司在任何情况下均无须以净现金结算担保行使。

b) 遗失、盗窃、毁坏或毁坏手令公司承诺,公司在收到合理令人满意的证据,证明其对本证书或任何与证券股份有关的股票证书的灭失、盗窃、毁坏或毁坏,以及在灭失、盗窃或毁坏其合理令人满意的赔偿或保证（如属证书,则该赔偿或保证不包括张贴任何债券）时,以及在交出和取消该证书或证券证书（如属证书被毁）时,本公司将制作及交付一份新的权证或股票证明书,以代替该等权证或股票证明书,而该等权证或股票证明书的日期为取消日期。

c）星期六、星期日、假期等如果采取任何行动的最后一天或指定日期或本文所要求或授予的任何权利的期满不是营业日,则可在下一个营业日采取该行动或行使该权利。

d）认可股份.

本公司承诺,在保证有效期内,它将从其授权和未经授权的普通股中保留足够数量的股份,以便在行使本保证下的任何购买权时发行保证股份。本公司进一步承诺,本授权书的发行应构成其负责在本授权书下行使购买权时发行必要授权股份的官员的完全权力。本公司将采取一切必要的合理行动,以确保该等权证股份可按本条例的规定发行,而不会违反任何适用的法律或规例,或违反任何可供普通股上市的交易市场的规定。本公司承诺,在保证有效期内,它将从其授权和未经授权的普通股中保留足够数量的股份,以便在行使本保证下的任何购买权时发行保证股份。本公司进一步承诺,本授权书的发行应构成其负责在本授权书下行使购买权时发行必要授权股份的官员的完全权力。本公司将采取一切必要的合理行动,以确保该等权证股份可按本条例的规定发行,而不会违反任何适用的法律或规例,或违反任何可供普通股上市的交易市场的规定。本公司承诺,凡在行使本担保所代表的购买权时可发行的所有担保股份,在行使本担保所代表的购买权时,以及在本担保所代表的该担保股份的付款后,将依照本法获得正式授权、有效发行、全额支付和不可转让,并免交所有税款,本公司就其发行而产生的留置权及收费（与该发行同时发生的任何转让除外） 。

除持有人放弃或同意外,本公司不得藉任何诉讼,包括但不限于藉任何重组、资产转让、合并、合并、解散、发行或出售证券或任何其他自愿行动,而避免或寻求避免遵守或履行本权证的任何条款,但在任何时候,善意协助执行所有必要或适当的条款,并协助采取一切必要或适当的行动,以保障持有人的权利不受损害。在不限制上述内容的一般性的情况下,本公司将（i）不会将任何证券股票的票面价值增加至高于在紧接证券价值增加之前行使证券价值时应支付的数额； （ii）采取一切必要或适当的行动,使本公司在行使本证券时能有效和合法地发行全额付款和不可转让的证券股票； （iii）利用商业上合理的努力获得所有这些授权为使公司能够履行本保证所规定的义务,公共管理机构如有需要,可给予豁免或同意。除持有人放弃或同意外,本公司不得藉任何诉讼,包括但不限于藉任何重组、资产转让、合并、合并、解散、发行或出售证券或任何其他自愿行动,而避免或寻求避免遵守或履行本权证的任何条款,但在任何时候,善意协助执行所有必要或适当的条款,并协助采取一切必要或适当的行动,以保障持有人的权利不受损害。在不限制上述内容的一般性的情况下,本公司将（i）不会将任何证券股票的票面价值增加至高于在紧接证券价值增加之前行使证券价值时应支付的数额； （ii）采取一切必要或适当的行动,使本公司在行使本证券时能有效和合法地发行全额付款和不可转让的证券股票； （iii）利用商业上合理的努力获得所有这些授权为使公司能够履行本保证所规定的义务,公共管理机构如有需要,可给予豁免或同意。

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered to the address for the Holder in the Warrant Register.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

NOTICE OF EXERCISE

To: CHINA JO-JO DRUGSTORES, INC.

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be delivered to the following DWAC Account Number:

_______________________________

_______________________________

_______________________________

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity: ________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: _________________________________________________

Name of Authorized Signatory: ___________________________________________________________________

Title of Authorized Signatory: ____________________________________________________________________

Date: ________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

18